Ledesma, JR, Ma, J., Zheng, P.
et al. Interferon-gamma release assay levels and risk of progression to active tuberculosis: a systematic review and dose-response meta-regression analysis.
BMC Infect Dis 21, 467 (2021). Accessed November 3, 2022.
https://doi.org/10.1186/s12879-021-06141-4Meermeier EW, Lewinsohn DM. Early clearance versus control: what is the meaning of a negative tuberculin skin test or interferon-gamma release assay following exposure to Mycobacterium tuberculosis? F1000Res. 2018;7:F1000 Faculty Rev-664. Published 2018 May 25. doi:10.12688/f1000research.13224.1
Pai M, Denkinger CM, Kik SV, et al. Gamma interferon release assays for detection of Mycobacterium tuberculosis infection. Clin Microbiol Rev. 2014;27(1):3-20. doi:10.1128/CMR.00034-13.
Ra SW, Lyu J, Choi CM, et al. Distinguishing tuberculosis from Mycobacterium avium complex disease using an interferon-gamma release assay. Int J Tuberc Lung Dis. 2011;15(5):635-640. doi:10.5588/ijtld.10.0485.
Stockbridge EL, Loethen AD, Annan E, Miller TL (2020) Interferon gamma release assay tests are associated with persistence and completion of latent tuberculosis infection treatment in the United States: Evidence from commercial insurance data.
PLOS ONE 15(12): e0243102. Accessed November 3, 2022.
https://doi.org/10.1371/journal.pone.0243102